AI Image
GLP-1 weight-loss drugs slow biological aging, recent studies show
NewsNation • • health
Key Points:
- Novo Nordisk and Eli Lilly have presented evidence that their GLP-1 weight-loss drugs can slow or even reverse biological aging in overweight or diabetic patients, as shown at the Aging Research & Drug Discovery conference.
- Using aging clocks that analyze DNA or proteins, Novo Nordisk found their semaglutide drugs (Ozempic and Wegovy) slowed biological aging by approximately two to three years in patients.
- Eli Lilly's research on its GLP-1 drug tirzepatide (Mounjaro and Zepbound) showed similar results, with epigenetic clocks indicating a significant reduction in biological age among users.
- Beyond weight loss, GLP-1 drugs have also been shown to improve kidney function, reduce blood pressure, and lower overall mortality risk.
- Experts caution that while these drugs show promise as geroprotectors in unhealthy populations, their effects on aging in healthy individuals remain unclear.
